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Cross-bridge kineticsHypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, increased ventricular
stiffness and impaired diastolic ﬁlling. We investigated to what extent myocardial functional defects can be
explained by alterations in the passive and active properties of human cardiac myoﬁbrils. Skinned
ventricular myocytes were prepared from patients with obstructive HCM (two patients with MYBPC3
mutations, one with a MYH7 mutation, and three with no mutation in either gene) and from four donors.
Passive stiffness, viscous properties, and titin isoform expression were similar in HCM myocytes and donor
myocytes. Maximal Ca2+-activated force was much lower in HCM myocytes (14±1 kN/m2) than in donor
myocytes (23±3 kN/m2; Pb0.01), though cross-bridge kinetics (ktr) during maximal Ca
2+ activation were
10% faster in HCM myocytes. Myoﬁbrillar Ca2+ sensitivity in HCM myocytes (pCa50=6.40±0.05) was
higher than for donor myocytes (pCa50=6.09±0.02; Pb0.001) and was associated with reduced
phosphorylation of troponin-I (ser-23/24) and MyBP-C (ser-282) in HCM myocytes. These characteristics
were common to all six HCM patients and may therefore represent a secondary consequence of the known
and unknown underlying genetic variants. Some HCM patients did however exhibit an altered relationship
between force and cross-bridge kinetics at submaximal Ca2+ concentrations, which may reﬂect the primary
mutation. We conclude that the passive viscoelastic properties of the myocytes are unlikely to account for
the increased stiffness of the HCM ventricle. However, the lowmaximum Ca2+-activated force and high Ca2+
sensitivity of the myoﬁlaments are likely to contribute substantially to any systolic and diastolic dysfunction,
respectively, in hearts of HCM patients.-NC-ND license. © 2010 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Hypertrophic cardiomyopathy (HCM) is a genetically-determined
disease that affects 1 in 500 people and which is characterized by
ventricular hypertrophy, interstitial ﬁbrosis, myocyte disarray and
diastolic dysfunction [1]. Its clinical outcomes range from entirely
asymptomatic disease to chronic progressive heart failure, arrhythmias
and sudden cardiac death [2]. Molecular genetic studies have led to the
concept of HCM as a disease of the sarcomere, since almost all of the
known HCM disease genes encode sarcomeric proteins, in particular
MYH7 (which encodes β-myosin heavy chain, β-MyHC) and MYBPC3
(encoding cardiac myosin binding protein-C, cMyBP-C), with eachaccounting for aboutone-thirdof the knownHCM-associatedmutations
[1–3]. However, it remains the case that 40–60% of HCM patients
screened appear to have no mutation in any sarcomeric protein so far
implicated in HCM [4,5].
The mechanisms linking myocardial dysfunction in human HCM,
either directly or indirectly, with changes in sarcomeric proteins are
unclear. The characteristic diastolic dysfunction (compromised myo-
cardial relaxation and passive ﬁlling) is largely a consequence of
increased ventricular stiffness, which may be due to the ventricular
hypertrophy, disarray of myocytes, interstitial ﬁbrosis, or possible
myocardial ischaemia [3,6]. However, there could also be an increased
intrinsic stiffness of the myocytes. Myocyte passive stiffness is largely
due to titin in the sarcomere [7–9] and an increase in the proportion of
the stiffer (N2B) isoform of titin relative to the more compliant (N2BA)
isoform was reported in an animal model of hypertrophy [10] and in
patients exhibiting diastolic heart failure with concentric LV
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contribute to the dynamic stiffness of the myocardium during chamber
ﬁlling, was increased in pressure-overload hypertrophy in animal
models [12]. However there has been no detailed investigation of the
passive viscoelasticity of humanmyocytes to examinewhether thismay
contribute to the increased stiffness of the HCM myocardium.
Systolic performance too is often compromised in HCM, particu-
larly during tachycardia. Cardiac output may be reduced by the
impairment of diastolic ﬁlling. In addition, in approximately 25% of
HCMpatients there is upper septal hypertrophy associatedwithmitral
valve dysfunction (systolic anterior motion), which obstructs the
outﬂow tract (hypertrophic obstructive cardiomyopathy, HOCM). It is
not clear whether there are also changes in the contractile properties
of myocytes that could either contribute to, or help to compensate for,
the altered cardiac function in HCM. Results from studies with
transgenic animals or isolated proteins have generally reported that
HCM is associated with increased myoﬁlament Ca2+ sensitivity, with
variable effects on maximum force or ATPase activity [13], though a
common (and perhaps unifying) feature is an increased energetic cost
of contraction [14]. In the only previous study (to our knowledge)with
myocytes from human HCM hearts, permeabilized (“skinned”)
ventricular myocytes from patients with one of two truncation
mutations in the MYBPC3 gene showed a reduced maximum steady-
state force production but elevated myoﬁbrillar Ca2+ sensitivity [15].
However, it was not clear whether these changes were speciﬁc to the
two MYBPC3 mutations studied or are a general characteristic of the
myocardium in all HCM patients. Furthermore, cross-bridge cycling
kineticswere not determined, so no inference could bemade about the
dynamics of myocardial contraction and relaxation in HCM.
To investigate the role of the myocytes in determining the passive
and active properties of the HCMmyocardium, we examined in detail
the steady-state and dynamic characteristics of passive stiffness and
active force production in themyocytes from a representative group of
HCM patients (with mutations in MYBPC3, MYH7, or neither gene),
compared with myocytes from non-diseased hearts. By comparing
results between individual patients, we exploredwhether the changes
in contractile phenotypewere gene-speciﬁc orwere common to all the
HCM patients. While passive viscoelasticity was not changed signif-
icantly, we found consistent alterations in the active properties of the
HCM myocytes that likely contribute to the pathophysiology of the
HCM myocardium. Most of these changes are likely to be secondary
consequences of the disease process.
2. Methods
Methods were modiﬁed from those described previously [16].
Details are given in the online Data Supplement. In brief, hypertro-
phied tissue was obtained from septal tissue removed during surgical
myectomy in HCMpatients and donor tissuewas obtained from the LV
free wall of unused donor hearts [17]. All tissue samples were ﬂash-
frozen in liquid N2. It is unlikely that HCM patients are a homogeneous
population (due to their different genotypes, drug treatments, co-
morbidities, etc.), so we studied sufﬁcient myocytes from each patient
to allow comparison between individual patients.
Mutation screening of the coding regions and splice sites of MYH7
andMYBPC3, the predominant HCM-associated genes, was carried out
[18]. Mutations were identiﬁed in patients M15 (MYBPC3 T2604A+C
deletion at 2605, predicted to encode a C-terminally truncated
protein), MA (MYBPC3 R502W), and ML (MYH7 R719Q), but the
other three HCM patients had no mutations in either gene.
Single skinned myocytes were prepared from the frozen tissue,
were glued between a force transducer and a motor (Fig. 1A) and set
to a sarcomere length (SL) of 2.0 μm in relaxing solution at 15 °C. SL
was measured by online video analysis. Myocyte passive viscoelas-
ticity and its SL dependence were measured using step increases of
cell length of 1 s duration (Fig. 1B). Each stretch induced a rapid rise inforce to a peak, followed by a slower decay in force (stress relaxation)
to reach a quasi-steady-state force (here termed “steady-state force”)
after 1 s. Stress relaxation is due to the viscoelastic properties of the
myocyte (i.e. of titin chieﬂy), while steady-state force is determined
by its elastic properties [19]. Since the SL reached in each length step
varied from myocyte to myocyte, we compared the force–SL
extension curves of different myocytes in two ways. In the ﬁrst
(Fig. 1C), we used the measured force–SL relationship in each
myocyte to estimate the force at SL=2.3 μm by interpolation. This
forcewas used as ameasure of stiffness in eachmyocyte. In the second
approach we grouped the values of SL reached in all myocytes during
the length step into bins of 0.1 μm wide; this was used to determine
the mean force–SL relationship and the parameters of stress
relaxation (Fig. 2).
Ca2+-activated force and the rate constant of force redevelopment
(ktr) were determined during maintained Ca2+ activation of the
myocytes. The ktr value is an indirect measure of cross-bridge cycling
kinetics that reﬂects the rate of cross-bridge reattachment and
transition to the force-generating state(s) [20]. The activatedmyocyte
was subjected to a rapid release/restretch protocol and ktr was
determined from a single exponential ﬁt to the force redevelopment
trace. Maximal force was normalized to myocyte cross-sectional area.
Force and ktr data were averaged from 3–10 myocytes from each
heart and this mean value was taken as a single datum point for the
calculation of the overall means. Unless stated otherwise, data points
show mean±SE for tissue from n=4 donor hearts and n=6 HCM
hearts.
3. Results
3.1. Passive stiffness and stress relaxation
Passive force was compared in skinned human donor and HCM
myectomy myocytes that were subject to a series of step stretches
(Fig. 1B). From the resulting force–SL relationship for each myocyte
(e.g. Fig. 1C) we estimated the peak and steady-state forces at 2.3 μm.
Fig. 1D shows the results for steady-state force in individual cells from
each donor and HCM patient. There was some variability between
myocytes taken from the same patient. Two myocytes had atypically
high stiffness, possibly due to adherent collagen (see later) and were
excluded from further analysis. The mean data (Fig. 1E) showed no
signiﬁcant difference between the stiffness of HCM and donor
myocytes, whether measured from peak force or steady-state force.
To examine the SL dependence of the time-independent (elastic)
and time-dependent (viscoelastic) components of the force response,
we grouped the SL values reached during the length steps into 0.1-μm-
wide bins (Fig. 2). The resulting force–SL relationships conﬁrmed that
the steady-state force increase was the same in HCM and donors over
the entire SL range, although there was a (non-signiﬁcant) tendency for
peak force to be higher in the HCM than donor myocytes at
SLsN2.15 μm. The viscoelastic properties of themyocyteswere assessed
from the rate and extent of stress relaxation during the 1 s length step.
Viscoelastic behavior caused passive force to fall by 40% during this step
(Fig. 2B). The half-time (t50) and relativemagnitude of stress relaxation
were found to be independent of SL andwere not signiﬁcantly different
betweendonor andHCMmyocytes (Fig. 2B andC), although therewas a
trend for t50 to be smaller (faster stress relaxation) in HCM myocytes.
We conclude that myocyte viscoelastic properties were not altered
signiﬁcantly in the HCM myocytes.
Titin is the major determinant of the passive viscoelasticity of
myocytes [7–9]. Titin protein isoform expression in the human donor
and HCM myocardium was therefore analyzed (Supplementary Data).
As found previously, human tissue contained both the N2B and N2BA
isoforms. The relative proportion of N2B (the shorter, stiffer isoform)
was not signiﬁcantly different in HCMand donormyocardium (69±2%,
n=6 and 61±2%, n=4, respectively). There was also no difference
Fig. 1. Passive force in skinnedmyocytes. (A) Typical donor skinnedmyocyte attached to the force transducer and servomotor. (B) Example of stretch protocol and force response. PF,
peak force; SSF, steady-state force. (C) Force–SL extension curves in a typical myocyte. Stiffness was assessed from the force at SL=2.3 μm. (D) Passive stiffness (heremeasured from
steady-state force) in 33 individual myocytes from 4 donor hearts (ﬁlled circles) and 30 from 6 HCM hearts (open circles). Squares show mean±SEM for each heart. Asterisks
indicate myocytes excluded from the calculation of means. (E) Mean stiffness data from peak force and steady-state force measurements in human donor myocytes (n=4) and HCM
myocytes (n=6).
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measured by the T2 band density relative to total titin (20±5% in HCM
vs. 23±5% in donor) and total titin protein, expressed relative to the
total expression ofMyHC protein (0.53±0.02 vs. 0.47±0.02, P=0.93).
3.2. Maximum Ca2+-activated force and cross-bridge kinetics
Fig. 3 shows the maximum Ca2+-activated force production for the
individual myocytes from donor and HCM hearts (panel A) and the
averaged data (panel B). Maximal isometric force in HCM myocytes
(14.2±1.3 kN/m2) was 40% smaller than in donor myocytes (23.4±
4.0 kN/m2).Myocytes fromdonor N8 exhibited a smaller force than the
other donors but we found no other functional or biochemical
differences in N8 compared with the other donors, so this sample was
included in the calculation of mean force (Fig. 3B); without this
inclusion, the difference in maximum force between HCM and donor
myocytes would have been even greater.
We investigated possible reasons for this large loss of force in HCM
myocytes compared with donor myocytes. One possibility was thatthe kinetics of cross-bridge cycling were altered substantially, e.g.
force would be reduced if attachment of cross-bridges to actin were
slower, or the detachment faster. To assess cross-bridge kinetics, we
measured the rate of force redevelopment (ktr) after forced
detachment of the cross-bridges. The ktr values at pCa 4.5 were
consistent within individual patients (Fig. 3C) and were 10% faster in
HCM myocytes than in donor myocytes (Fig. 3D). The force and ktr
data are consistent with a faster cross-bridge detachment, rather than
slower attachment, in HCM myocytes (see Discussion).
3.3. Structure of myocytes
Another possible reason for the reduced forcewas disruption or loss
of myoﬁbrils in HCM myocytes. Videomicroscopy of skinned myocytes
(Fig. 4A) revealed a somewhat distorted striation pattern in HCM
myocytes and a slightly shorter resting SL (1.73±0.01 μm) than in
donor myocytes (1.78±0.01 μm; n=4, 21 myocytes each; Pb0.001).
Confocal microscopy (Fig. 4B) conﬁrmed the slight disorder of the
sarcomeres in HCM myocytes. However, staining with antibodies
Fig. 2. Sarcomere length dependence of passive force and viscoelasticity in skinned donormyocytes (ﬁlled symbols) and HCMmyocytes (open symbols). Datawere grouped into 0.1-μm-
wide ‘bins’ according to the SL reached during the length step and the averages were calculated for each heart. Symbols showmean±SE from 4 donor and 6 HCM hearts. (A) Peak and
steady-state forces. (B) Amplitude of force decay during stress relaxation, expressed as the steady-state force divided by the peak force. (C) Mean half-time of force decay (t50).
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myoﬁbrils in the HCM myocytes, although precise quantitative studies
could not be carried out. This suggests that the large reduction of
maximum force could not be explained by loss of myoﬁbrils.
Interestingly, in the donor samples collagen IV ﬁbers were often
associated intimately with the myocytes and exhibited a partially
striated pattern at the level of the Z-disc, reﬂecting the arrangement of
costameres (arrowheads, Fig. 4B, panels e and f). It is possible that
similar collagen, running along the length of the myocyte, may have
accounted for the abnormally high stiffness seen in some myocytes in
Fig. 1D. Although there was generally more collagen IV in the HCM
myocytes, this tended to be found in clumps and the association with
costameric structures was much less pronounced than in donor
myocytes.
3.4. Ca2+ sensitivity of force and cross-bridge cycling kinetics
In intact cardiac myocytes the Ca2+ transient does not activate the
myoﬁbrils fully, so it is essential to determine myoﬁbrillar properties
at submaximal levels of activation. The Ca2+ sensitivity was consis-
tently higher for the HCM skinned myocytes than for the donors, as
shown by the average force–pCa curves (Fig. 5A) and the individual
pCa50 values (Fig. 5B). Themean pCa50 valueswere 6.40±0.05 (n=6)
for HCMmyocytes and 6.09±0.02 (n=4) for donor (P=0.001),while
the steepness of the force–pCa relationshipwas unchanged (nH valuesof 3.73±0.56 and 2.95±0.12, respectively; PN0.05). This increase in
Ca2+ sensitivity causes the inhibitory effect of the reduced maximum
force to be overcome for pCa values above ~6.2 (dashed line, Fig. 5A).
Myoﬁbrillar Ca2+ sensitivity is inﬂuenced by protein kinase A
(PKA)-mediated phosphorylation of troponin-I and possibly MyBP-C.
Analysis using phosphorylation-speciﬁc antibodies revealed that
phosphorylation of TnI (ser-23/24) sites and of MyBP-C (ser282)
were signiﬁcantly lower in HCMmyocardium than in donor myocytes
(Fig. 5C and D). To investigate whether the lower phosphorylation
could account for the higher Ca2+ sensitivity of the HCMmyocytes, we
compared the Ca2+-shortening relationships in skinned, unattached
myocytes with and without incubation in PKA. With HCM myocytes,
PKA phosphorylated TnI and MyBP-C (see Data Supplement) and
decreased myoﬁbrillar Ca2+ sensitivity (Fig. 5E), whereas with donor
myocytes there was little change in phosphorylation or myoﬁbrillar
Ca2+ sensitivity, leading to the difference in Ca2+ sensitivity between
the HCM and donor myocytes being reduced by about one-half. Thus
the differing Ca2+ sensitivity of the myocytes under basal conditions
was partly due to differences in phosphorylation at PKA sites.
Fig. 6 shows how both cross-bridge kinetics (ktr) and force (i.e. the
level of thin ﬁlament activation) changed as the bathing Ca2+
concentration was altered. As found previously with human myoﬁ-
brils [16], ktr increased as [Ca2+] (and force) was raised, and this was
true for both donor and HCMmyocytes. The ktr–force relationships for
the HCM patients at submaximal Ca2+ concentrations were generally
Fig. 3. Isometric force and cross-bridge kinetics in skinned myocytes at maximal Ca2+ activation (pCa 4.5). (A) Data from individual myocytes (circles) and mean data (squares).
Symbols as in Fig. 1. (B) Mean force data (n=4 donor hearts and 6 HCM hearts). (C) Rate constant of force redevelopment (ktr). Inset: example of force redevelopment in a skinned
donor myocyte after rapid release/restretch, and ﬁtted single exponential curve. (D) Mean ktr data.
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showed greater ktr values at submaximal force levels (i.e. faster cross-
bridge kinetics for a given level of thin ﬁlament activation), whereas
patient MM tended to have the slowest kinetics. Overall, there was no
consistent difference between the Ca2+ regulation of cross-bridge
kinetics between HCM and donor patients.
3.5. Analysis of contractile proteins
Analysis of 12.5% polyacrylamide gels showed that, relative to
actin, the expression of TnT, MLC-2 and MyHC protein did not differ
signiﬁcantly between donor myocardium and HCM myocardium, nor
did the phosphorylation level of MLC-2 (see Supplement).
4. Discussion
This study is the ﬁrst to examine both the steady-state and dynamic
properties of passive viscoelasticity and Ca2+-activated contractions in
skinned myocytes from patients with obstructive HCM, although van
Dijk et al. [15] have previously reported steady-state force measure-
ments in myocytes from a set of HCM patients with truncation
mutations in the MYBPC3 gene. Our HCM unselected cohort contained
two patients with mutations inMYBPC3, one with a mutation inMYH7,
and three with no mutation in either gene. These ratios are
representative of HCM patients in general, in whom mutations in
MYBPC3 and MYH7 have been found in 16–26% and 14–19%,
respectively, of patients, while 40–60% of patients had no mutation in
the genes for the main sarcomeric proteins [4,5]. Furthermore, weobtained sufﬁcient data from individual patients to allow us to compare
between them, in order to examine whether the changes we observed
were speciﬁc to the particular MYBPC3 or MYH7 mutation, or were
common to all the HCM patients. We found the passive elastic and
viscous properties of the HCMmyocytes were similar between patients
and were not signiﬁcantly different from those of donor myocytes. In
contrast, the maximum Ca2+-activated force of myocytes from HCM
patients was decreased by 40% compared with donor myocytes, while
the Ca2+ sensitivity of force productionwas substantially greater. These
functional changes, which could adversely affect both diastolic and
systolic function, were seen in all our HCM patients, suggesting they are
secondary consequences of the underlying genetic differences between
patients. However there was some evidence that differences between
the HCM patients could be revealed by cross-bridge cycling kinetics at
submaximal Ca2+ activation.4.1. Myocyte viscoelasticity
While measurements in vivo have shown an increase in chamber
stiffness in the hypertrophied heart [21], it is not knownwhether this is
due in part to changes in the passive properties of themyocytes. During
diastolic ﬁlling myocyte length increases continuously, so the passive
stiffness of the myocytes during this period depends upon both their
elasticity (length-dependent) and viscoelasticity (velocity-dependent).
Previous studies have reported that pressure-overload hypertrophy in
animals and humans is associated with increased myocyte stiffness
resulting from an increased titin N2B:N2BA ratio [10,11] or with
increased myocyte viscosity resulting from microtubule proliferation
Fig. 4. Structure of typical donor myocytes (patient N12) and HCMmyocytes (patient M15). (A)Myocyte video images from the computer screen. (B) Confocal images using primary
antibodies as follows: a–d (a and b overview; c and d high magniﬁcation), polyclonal rabbit anti-titin m8 to visualize the myoﬁbrils (green), monoclonal mouse anti-collagen IV to
stain for extracellular matrix (red), DAPI (blue) for nucleus; e and f, collagen IV (same ﬁeld as c and d); g and h, sarcomeric α-actinin (red), nucleus (blue). HCMmyocytes showed
increased collagen IV around the myocytes but an absence of the regular arrangement of collagen IV seen on the surface of donor myocytes (compare arrowheads in e and f).
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Fig. 5. Ca2+ sensitivity of force in donor myocytes (ﬁlled symbols) and HCMmyocytes (open symbols). (A) Mean force–pCa curves for the 4 donor patients (28 myocytes) and HCM
patients (32myocytes). Force was normalized to themaximum force (pCa 4.5). Dashed line shows themean HCM curve factoring in the depression of maximum force. (B) Individual
and mean pCa50 values for the individual patients. (C) Representative Western blots for phosphorylated cTnI (ser-23/24), cMyBP-C (ser-282) and α-actinin (loading control) in one
donor and one HCM sample. (D) Mean data. (E) Mean shortening–pCa relationships in unrestrained myocytes (n=14–16 myocytes per group).
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not signiﬁcantly different between HCM and donor myocytes (Figs. 1
and 2). The passive viscoelastic behavior of themyocyte is thought to be
due to the unfolding of titin's globular domains [9] and to titin's
interactions with actin [22]. Consistent with the functional data, there
was no signiﬁcant difference in the titin N2B/N2BA isoform ratio
between HCM and donor myocytes. Thus the myocytes from our HCM
patients exhibited no enhancement of dynamic or static stiffness that
could contribute to the increased diastolic stiffness characteristic of
hypertrophied myocardium. This contrasts with other studies with
ischemic or dilated cardiomyopathy, in which changes in stiffness and
the titin isoform ratio were reported to either cause, or compensate for,
changes in the elastic component of tissue stiffness [23]. We conclude
that the higher stiffness of the HCMmyocardium is due to factors other
than myocyte viscoelasticity, such as the disarray of myocytes and
increased tissue ﬁbrosis [6].4.2. Maximum force production
A major difference in the active properties of the HCM and donor
myocytes was found with maximum Ca2+-activated force, which was
decreased by about 40% inHCMcomparedwith donormyocytes (Fig. 3).
The large loss of force-producing capacity can account for the smaller
contraction of intactmyocytes from similarmyectomy samples [17] and
would tend to cause systolic dysfunction in the intact heart.
We found no change in protein content of the myoﬁbrils that could
explain this large loss of force. Although therewas no evidence for a loss
of myoﬁbrils (Fig. 4), HCM myocytes did have a somewhat less
organized sarcomere alignment than donor myocytes. Depending on
the precise derangements at themolecular level, this might cause a loss
of force, though further work is needed to explore this. Another
possibility is that the decrease in maximal force was due to a reduction
in the number of attached, force-producing cross-bridges per
Fig. 6. Relationship between cross-bridge cycling kinetics and force in donor myocytes
(ﬁlled symbols) and HCM myocytes (open symbols) at different levels of Ca2+
activation. Each point shows the force and ktr values (with standard errors) measured in
myocytes from the same heart at each Ca2+ concentration. Averages of 4 donor hearts
and 6 HCMhearts. The force–ktr relationships were similar in donor and HCMmyocytes,
except for myocytes from two HCM patients (dashed lines).
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and transition to force-producing states (fapp) or a greater rate of
detachment (gapp). Maximum ktr (which is∝ fapp+gapp) [20]was ~10%
faster in HCMmyocytes (Fig. 3D), which is not consistent with a slower
fapp. A faster gapp would however both increase ktr and decrease force. If
we assume that 50% of cross-bridges (∝ fapp/[fapp+gapp]) are attached
at maximal Ca2+ (so fapp=gapp), then the 10% increase in ktr could be
caused by a 20% increase in gapp, whichwould lower force by 9%. Thus a
faster gapp could explain someof the reduced force inHCMmyocytes but
theremust be additional factors, such as fewer cycling cross-bridges or a
decrease in the force produced per cross-bridge. Using myosin isolated
frommyectomies similar to ours, in an in vitromotility assay the fraction
of ﬁlaments motile was reduced by 19% [17], which suggested a fall in
the population of active myosins due to alterations in myosin itself; a
similar fall in the number of active cross-bridges would contribute
substantially to the decrease in force observed here.
An important question is whether the decrease in maximum force
is directly due to the mutations in the HCM patients, or to secondary
changes. This question cannot be answered deﬁnitively with human
studies, since human tissue is necessarily obtained only during
surgery on patients who are already symptomatic and in whom any
primary defect has likely caused many secondary changes. Neverthe-
less, our ﬁnding (Figs. 3 and 5) that a similar contractile phenotype is
seen in myocytes from six unrelated HCM patients (with different
mutations in MYBPC3 or MYH7, or neither of these), measured under
identical conditions, suggests that the contractile deﬁciency is a
common consequence of HCM, secondary to the initial abnormalities
produced by the known and unknown genetic variant(s) underlying
the cardiomyopathy [17]. By analogy, we suggest that similar
secondary changes may account for the reduced maximum force
production observed in HCM myocytes with another MYBPC3
mutation [15] or in HCM myoﬁbrils with the MYH7 R403Q mutation
[24].
4.3. Myoﬁbrillar Ca2+ sensitivity
HCM myocytes were more Ca2+-sensitive than donor myocytes,
with pCa50 elevated by 0.31 units, corresponding to a 50% reduction in
the [Ca2+] required for half-maximal activation of force (Fig. 5). This
disparity was due, at least in part, to the very low levels of
phosphorylation in TnI at ser-23/24 sites and MyBP-C at ser-282 (Fig.
5C and D), since the difference in Ca2+ sensitivity was much reducedafter incubation in PKA(Fig. 5E).Whether thedifference remainingafter
PKA reﬂects a primary inﬂuence of an underlyingmutation, as has been
found in animal models of HCM [13], remains to be established. Our
results differ somewhat fromthoseof vanDijk et al. [15],who reported a
reduction in TnI phosphorylation but unchanged MyBP-C phosphory-
lation inHCMpatientswith truncationmutations inMYBPC3. vanDijk et
al. suggested that the contractile dysfunction might be caused by the
differential phosphorylation of TnI and MyBP-C, but this explanation is
unlikely to apply to our patients, who exhibited reduced phosphoryla-
tion of both TnI and MyBP-C.
One caveat with all studies like these is that the phosphorylation
status of the biopsies may be inﬂuenced by the drug treatment of the
patients immediately prior to biopsy retrieval. In particular, the donor
hearts may show elevated phosphorylation due to inotropic drug
support prior to cardiac explantation [25], which may exaggerate the
difference in Ca2+ sensitivity observed here. Nevertheless, it seems
likely that the high Ca2+ sensitivity observed with HCM myocytes
reﬂects the situation in vivo. This elevated Ca2+ sensitivity would tend
tomaintain contractile strength in the face of the reduced contractility
(dashed line, Fig. 5A), which may help explain why systolic function
may not be compromised in HCM patients. On the other hand, this
increase in Ca2+-responsiveness would, by causing a large relative
enhancement of force at Ca2+ concentrations just above threshold
(Fig. 5A), tend to slow ventricular relaxation and enhance diastolic
stiffness in intact myocytes. This myoﬁlament-based factor could thus
contribute to poor diastolic function of the HCM myocardium in vivo.
Finally, a raised Ca2+ sensitivity may increase the risk of arrhythmias
[26], which is a characteristic feature of HCM.4.4. Cross-bridge kinetics
The cycling rate of activated cross-bridges is a major determinant
of the kinetics of force development and relaxation in the myocar-
dium [27], and is therefore a key factor regulating the contractility of
the heart. Cross-bridge cycling kinetics (ktr) during maximal Ca2+
activation were 10% faster in HCMmyocytes than in donors (Fig. 3D).
This distinguishes the contractile phenotype from end-stage heart
failure, where the cross-bridges are usually slower than normal, due
to a decrease in the α:β MyHC isoform ratio [28]. It has been shown
that re-expression of atrial light chain-1 (ALC-1) in hypertrophied
ventricular myocardium is associated with a faster ktr [29]. While we
did not detect expression of ALC-1 in our HCM biopsies using 1-D gels,
increased ALC-1 expression was detected in similar HCM biopsies
using 2-D gels [17], so this is a possible cause of the faster maximum
cross-bridge cycling kinetics in our experiments.
More appropriate for the intact heart are cross-bridge kinetics under
the physiologically relevant conditions of submaximal Ca2+ activation
(Fig. 6). In most HCM patients the relative force–ktr relationship was
similar to donors, implying no inherent change in the Ca2+ regulation of
cross-bridge cycling kinetics. (Note that for the analysis in Fig. 6 we
assume that the observed reduction inmaximumCa2+activated force is
due to fewer active cross-bridges, with no change in force per attached
cross-bridge). However, patient M15 exhibited submaximal ktr values
above those for the other human samples. Interestingly, this mutation
(MYBPC3 T2604A+C deletion at 2605) encodes for a C-terminally
truncated cMyBP-C that leads to a 35% reduction of cMyBP-C content in
this patient [18]. There is evidence that cMyBP-C functions as a
phosphorylation-sensitive “brake” on cross-bridge movement towards
the thin ﬁlament, because cross-bridge cycling is increased by
phosphorylation of cMyBP-C or by the absence of cMyBP-C in KO mice
[30]. It therefore possible that the faster cross-bridge kinetics in M15
results from theMyBP-Chaploinsufﬁciency in this patient. Therewas no
clear acceleration of kinetics with the otherMYBPC3mutation, but this
patient (MA) has a missense mutation that is associated with a much
smaller (17%) reduction in cMyBP-C than with patient M15 [18].
745A.C. Hoskins et al. / Journal of Molecular and Cellular Cardiology 49 (2010) 737–745The third mutation we found (MYH7 R719Q) was in patient ML.
This mutation has previously been shown to reduce sliding velocity in
a motility assay with Dictyostelium myosin [31] or increase it in
human slowmuscle ﬁbers [32]. We found that this mutation led to no
obvious alteration in isometric cross-bridge cycling kinetics at
physiological levels of Ca2+ activation. Thus ﬁndings from model
systems should be extrapolated to the human myocardium with care.
It should be noted that our kinetic data do not conﬁrm or refute the
concept that HCM is associated with inefﬁcient ATP utilization by the
myoﬁlaments [14]. In some of our HCM samples the cross-bridge
kinetics at submaximal Ca2+ activation tended to be faster than in
donors and in some they tended to be slower. However simultaneous
measurements of ATPase activity and force would be required to
directly assess efﬁciency of chemomechanical transduction in these
patients.
In summary, this study reports the static and dynamic properties
of skinned myocytes from a representative group of patients with
hypertrophic cardiomyopathy. Myocyte passive properties were no
different in HCM and donor myocytes, which suggests that other
factors are responsible for the increased stiffness of the intact
ventricle. HCM myocytes exhibited a large decrease in maximum
Ca2+ activated force, which if representative of myocytes in the intact
myocardium, would tend to cause systolic dysfunction. Counteracting
this would be the enhanced myoﬁbrillar Ca2+ sensitivity in HCM
myocytes, but this factor would tend to slow relaxation and contribute
to diastolic dysfunction in the intact heart. Thus the properties of the
myocytes likely contribute to both the systolic and diastolic
contractile dysfunction of the HCM heart.
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